Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.
Human Genetics|July 1, 1997
Identification of novel 'expressed sequence tags' within the FHIT gene locus in human chromosome region 3p14.2A Lux, W Bardenheuer, D Michael, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1984
The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexesB Wappes, M Jennerwein, E von Angerer, et al.
European Journal of Haematology|February 1, 1992
A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemiaO Kloke, U Wandl, B Opalka, et al.
British Journal of Cancer|December 22, 1999
Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell linesU Vanhoefer, M R Müller, R A Hilger, et al.
Anti-Cancer Drugs|October 17, 1998
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistanceA Harstrick, A Gonzales, N Schleucher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2003
Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patientsM R Nowrousian, S Waschke, P Bojko, et al.
Archiv Der Pharmazie|January 1, 1989
Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: SynthesisM Jennerwein, R Gust, R Müller, et al.
Seminars in Oncology|June 1, 1997
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancerU Gatzemeier, C Manegold, W Eberhard, et al.
The Journal of Gene Medicine|March 30, 2000
Insertion of natural intron 6a-6b into a human cDNA-derived gene therapy vector for cystic fibrosis improves plasmid stability and permits facile RNA/DNA discriminationA C Boyd, F Popp, U Michaelis, et al.
Pageof 26